Enabling high product quality, and yield through process optimization for biologics
Learn how Syngene’s expertise in process optimization enabled a biopharma company to achieve high product quality and yield for its PPQ batches, including enabling appropriate scale-up to commercial.
Long acting injectables: Accelerating the path to patient wellbeing
Learn about the various challenges in developing LAIs and the technologies and techniques being used by Syngene to help clients use this transformative drug delivery system to treat chronic diseases.
Developing a green synthesis process for a growth promoter drug for animals
Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.
Reducing variability in gene expression: Bottlenecks and Solutions
Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
Enabling a four-fold increase in titer for mAb manufacturing using Syngene’s platform process
Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.
IND-enabling safety tox studies for FDA submission in just 9 months
Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.
Developing a unique hybridoma platform for manufacturing mAb cocktail formulations
Learn how Syngene developed a unique hybridoma platform for manufacturing mAb cocktail formulations for use in reagent kits designed to activate and expand human T cells for immunotherapy in patients.
Harnessing the immune system for cancer cell-therapy
Explore the top challenges in developing CAR-T therapy for treating cancer and how leading CRO-CDMO Syngene supports clients in bringing this therapy to patients faster.
Development of a Scalable Process for the Synthesis of Cyclopropyl-Methyl-Proline with Complex Stereochemistry: A Key Building Block of Factor D Inhibitors
Publication: ACS Publications
Quantifying a biomarker in mice brain for treating mood and anxiety disorders
A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
